Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Liminal BioSciences Inc is a biotechnology business based in the US. Liminal BioSciences shares (LMNL) are listed on the NASDAQ and all prices are listed in US Dollars. Liminal BioSciences employs 251 staff and has a trailing 12-month revenue of around USD$3.3 million.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Active traders
52-week range | USD$3.51 - USD$21.29 |
---|---|
50-day moving average | USD$4.4538 |
200-day moving average | USD$5.2961 |
Wall St. target price | USD$9.98 |
PE ratio | 2.3681 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-12.8072 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Liminal BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Liminal BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Liminal BioSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Liminal BioSciences shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Revenue TTM | USD$3.3 million |
---|---|
Gross profit TTM | USD$-55,542,000 |
Return on assets TTM | -41.58% |
Return on equity TTM | -222.18% |
Profit margin | 0% |
Book value | N/A |
Market capitalisation | USD$123.1 million |
TTM: trailing 12 months
There are currently 285,673 Liminal BioSciences shares held short by investors – that's known as Liminal BioSciences's "short interest". This figure is 4.8% down from 300,041 last month.
There are a few different ways that this level of interest in shorting Liminal BioSciences shares can be evaluated.
Liminal BioSciences's "short interest ratio" (SIR) is the quantity of Liminal BioSciences shares currently shorted divided by the average quantity of Liminal BioSciences shares traded daily (recently around 529024.07407407). Liminal BioSciences's SIR currently stands at 0.54. In other words for every 100,000 Liminal BioSciences shares traded daily on the market, roughly 540 shares are currently held short.
However Liminal BioSciences's short interest can also be evaluated against the total number of Liminal BioSciences shares, or, against the total number of tradable Liminal BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Liminal BioSciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Liminal BioSciences shares in existence, roughly 10 shares are currently held short) or 0.0299% of the tradable shares (for every 100,000 tradable Liminal BioSciences shares, roughly 30 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Liminal BioSciences.
Find out more about how you can short Liminal BioSciences stock.
We're not expecting Liminal BioSciences to pay a dividend over the next 12 months.
Liminal BioSciences's shares were split on a 1:1000 basis on 4 July 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Liminal BioSciences shares – just the quantity. However, indirectly, the new 99900% higher share price could have impacted the market appetite for Liminal BioSciences shares which in turn could have impacted Liminal BioSciences's share price.
Over the last 12 months, Liminal BioSciences's shares have ranged in value from as little as $3.51 up to $21.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Liminal BioSciences's is 1.4352. This would suggest that Liminal BioSciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Liminal BioSciences Inc. , a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of idiopathic pulmonary fibrosis and respiratory diseases. The Plasma-Derived Therapeutics segment focused on the development of its plasma-derived product candidate Ryplazim, a purified glu-plasminogen derived from human plasma that acts as a plasminogen replacement therapy for patients deficient in plasminogen protein. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc.
Steps to owning and managing TREB-U, with 24-hour and historical pricing before you buy.
Steps to owning and managing TIG, with 24-hour and historical pricing before you buy.
Steps to owning and managing TDAC, with 24-hour and historical pricing before you buy.
Steps to owning and managing TREB, with 24-hour and historical pricing before you buy.
Steps to owning and managing TREB-WS, with 24-hour and historical pricing before you buy.
Steps to owning and managing TDG, with 24-hour and historical pricing before you buy.
Steps to owning and managing TACT, with 24-hour and historical pricing before you buy.
Steps to owning and managing TT, with 24-hour and historical pricing before you buy.
Steps to owning and managing TROX, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVG, with 24-hour and historical pricing before you buy.